Physician

Ghulam Rabbani Aziz, M.D.

According to 2025 Medicare claims, Ghulam Aziz, M.D. (NPI: 1366443343) practices pulmonary disease in the Weirton-Steubenville, WV-OH market, with the plurality of this provider's patient population coming from Jefferson, OH. This provider's primary affiliated billing organization is TRI STATE LUNG & SLEEP ASSOCIATES, INC (NPI: 1356371561; TIN: 753020102) and primary practice location at 43920-9449.

Aziz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 817 traditional Medicare patients, billed 3,967 HCPCS/CPT codes, and received $226,713 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 6,397 prescription claims across 723 beneficiaries totaling $3,385,162 in drug costs, led by Ofev (Nintedanib Esylate). DME data shows 4,431 claims. Open Payments data shows 90 records totaling $1,463. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $576,979 to $226,713. In contrast, Part D prescription costs have moved sharply higher in recent years, from $714,781 to $3,385,162. For DME billing, reported payments rose steadily, from $225,156 to $233,271.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	938	10,657	$576,979
2016	1,068	10,521	$597,690
2017	984	8,782	$477,434
2018	994	7,280	$395,464
2019	1,020	6,351	$367,903
2020	944	5,723	$406,069
2021	966	5,284	$393,107
2022	927	4,665	$298,917
2023	889	4,218	$266,723
2024	817	3,967	$226,713

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	543	3,721	$714,781
2016	555	4,145	$849,252
2017	531	3,941	$1,023,933
2018	562	4,168	$1,288,066
2019	602	4,491	$1,528,573
2020	600	4,873	$1,823,639
2021	667	5,076	$2,499,407
2022	644	5,078	$3,419,402
2023	700	5,936	$4,102,751
2024	723	6,397	$3,385,162

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	922	3,597	$264,174
2016	1,215	4,046	$188,701
2017	1,223	4,299	$165,736
2018	1,274	4,247	$183,469
2019	1,421	4,759	$220,737
2020	1,423	4,625	$247,630
2021	1,355	4,458	$238,788
2022	1,386	4,543	$277,600
2023	1,470	4,686	$282,996
2024	1,453	4,431	$258,873

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	296	393	$86
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	168	633	$60
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	292	403	$60
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	176	571	$37
94060	Test to measure expiratory airflow and volume changes before and after medication administration	338	353	$23

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ofev	Nintedanib Esylate	67	2,070	$942,894
Prolastin C	Alpha-1-Proteinase Inhibitor	33	896	$311,533
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	351	12,450	$259,295
Spiriva Respimat	Tiotropium Bromide	375	14,008	$240,674
Breo Ellipta	Fluticasone/Vilanterol	390	15,420	$202,359

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	67	484	$47,717
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	46	$37,911
A7030	Full face mask used with positive airway pressure device, each	N	124	268	$27,952
A7031	Face mask interface, replacement for full face mask, each	N	102	254	$27,792
E0601	Continuous positive airway pressure (cpap) device	Y	67	347	$12,166

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	90	$1,463	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ghulam Rabbani Aziz, M.D.?

Tedicare shows public-source Medicare data for Ghulam Rabbani Aziz, M.D. (NPI 1366443343), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ghulam Rabbani Aziz, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ghulam Rabbani Aziz, M.D.?

Ghulam Rabbani Aziz, M.D. is linked to TRI STATE LUNG & SLEEP ASSOCIATES, INC (billing NPI 1356371561) in the available physician profile data.

Does Ghulam Rabbani Aziz, M.D. have Open Payments data?

Ghulam Rabbani Aziz, M.D. has 90 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.